Ultrasound is integral to the management of thyroid nodules. However, the interpretation of thyroid ultrasound studies is time- and training-intensive and has inherent inter-observer inconsistencies, resulting in a decrement in its positive predictive value (1). Compounding these limitations, fine-needle aspiration (FNA) yields 15% to 30% cytologically indeterminate nodules, which often leads to unnecessary diagnostic surgeries (2). This spurred the initiation of a new research space where artificial intelligence (AI) is steered to improve preoperative sonographic risk stratification of thyroid nodules, and to minimize overdiagnosis and overtreatment of thyroid cancer. Li et al. conducted a multi-institutional effort to use AI-enabled algorithms that appear to supersede the previous machine learning sonographic classifiers of thyroid nodules (3). To that end, they used a large sonographic set of more than 300,000 images, thereby eliminating a common barrier to similar studies—the lack of sufficiently large curated datasets. Li et al. compared their deep convolutional neural network (DCNN) model’s performance against the judgment of expert radiologists per the standard Thyroid Imaging Reporting and Data System (TI-RADS) guidelines and pathological examination results, which represent the gold standard for diagnosis (4).

Previously, there has been an unmet clinical need to grow out of the traditional machine learning thyroid nodule classifiers with their inherent pitfalls such as dependence on expert-designated features as inputs (5). However, Li et al. successfully demonstrate the capacity of a performance-weighted combination of two of the most popular deep learning classification models (i.e., ResNet-50 and Darknet-19 CNN architectures) to rapidly-provide promising results in a real-world setting. The DCNN model from Li et al. showed superior specificity and accuracy, and similar sensitivity to expert radiologists’ judgment, all in the setting of an externally validated study. The latter suggested model generalizability.

 Appropriately, the authors reported caveats to their work including the absence of multicenter training cohorts and not fully accounting for the potential confounding effect of nodule size and thyroid cancer subtypes, and an almost exclusively northern Han Chinese population. Nevertheless, this study offers valuable insights into the implications of deep learning in thyroid nodules sonographic risk

---

**Editorial Commentary**

**Real-world applications of deep convolutional neural networks in diagnostic cancer imaging**

Hesham Elhalawani¹, Pei Yang², Mohamed Abazeed¹,², Chirag Shah¹, Abdallah S. R. Mohamed⁴, Charles R. Thomas Jr⁵, Clifton D. Fuller⁴,⁵, Reid F. Thompson⁶

¹Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH, USA; ²Key Laboratory of Translational Radiation Oncology, Hunan Cancer Hospital, Xiangya Medical School, Central South University, Changsha 410013, China; ³Department of Translational Hematology Oncology Research, Cleveland Clinic, Cleveland, OH, USA; ⁴Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; ⁵Radiation Medicine, Oregon Health & Science University, Portland, OR, USA; ⁶Hospital & Specialty Medicine, VA Portland Healthcare System, Portland, OR, USA

**Correspondence to:** Hesham Elhalawani, MD, MSc. Department of Radiation Oncology, Cleveland Clinic, 9500 Euclid Ave CA-50, Cleveland, OH 44106, USA. Email: elhalawani.hesham@gmail.com.

**Provenance:** This is an invited article commissioned by the Section Editor Dr. Shi-Tong Yu (Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China).


Submitted Nov 24, 2019. Accepted for publication Dec 20, 2019.

doi: 10.21037/cco.2020.01.02

View this article at: http://dx.doi.org/10.21037/cco.2020.01.02
AI is invariably changing the oncology landscape and the efforts by Li et al. represent one benchmark for future AI algorithm development for thyroid nodules risk stratification. They provide a real potential for transforming this capability into a widely applicable clinical tool. However, what Li et al. make abundantly clear is that their model is complementary to rather than a substitute for manual diagnosis of thyroid cancer, reinforcing the importance of the partnership between clinicians and AI experts. Consequently, the oncology community must embrace and invest in AI via personnel education, collaborative research, and resource allocation in order to create more innovative solutions for real-world clinical challenges.

Acknowledgments

Funding: Dr. Clifton D. Fuller received US federal funding and salary support unrelated to this project from the National Institutes of Health (NIH), including: the National Institute for Dental and Craniofacial Research Establishing Outcome Measures Award (1R01DE025248/ R56DE025248) and an Academic Industrial Partnership Grant (R01DE028290); NCI Early Phase Clinical Trials in Imaging and Image-Guided Interventions Program (1R01CA218148); an NIH/NCI Cancer Center Support Grant (CCSG) Pilot Research Program Award from the UT MD Anderson CCCS Radiation Oncology and Cancer Imaging Program (P30CA016672) and an NIH/NCI Head and Neck Specialized Programs of Research Excellence (SPORE) Developmental Research Program Award (P50 CA097007). Dr. Fuller received funding and salary support unrelated to this project from: National Science Foundation (NSF), Division of Mathematical Sciences, Joint NIH/ NSF Initiative on Quantitative Approaches to Biomedical Big Data (QuBBD) Grant (NSF 1557679); NSF Division of Civil, Mechanical, and Manufacturing Innovation (CMMI) standard grant (NSF 1933369) a National Institute of Biomedical Imaging and Bioengineering (NIBIB) Research Education Programs for Residents and Clinical Fellows Grant (R25EB025787-01); the NIH Big Data to Knowledge (BD2K) Program of the National Cancer Institute (NCI) Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science Award (1R01CA214825). Direct infrastructure support for Dr. Fuller is provided by the multidisciplinary Stiefel Oropharyngeal Research Fund of the University of Texas MD Anderson Cancer Center Charles and Daneen Stiefel Center for Head and Neck Cancer and the Cancer Center Support Grant (P30CA016672) and the MD Anderson Program in Image-guided Cancer Therapy. Dr. Fuller has received direct industry grant support, honoraria, and travel funding from Elekta AB. Dr. Reid F. Thompson was supported by the U.S. Department of Veterans Affairs under award number 1IK2CX002049-01.

Footnote

Conflicts of Interest: Dr. Pei Yang: kq1801105, Changsha
Science and Technology Bureau. Dr. Mohamed Abazeed: Bayer AG, grant support, travel support and honorarium; Siemens Healthcare, USA, grant support. Dr. Chirag Shah: Consultant- Impedimed, Grants- Varian Medical Systems, PreludeDX, VisionRT. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.

References


